Literature DB >> 19000059

Human polyomaviruses and cancer: expanding repertoire.

Ugo Moens1, Mona Johannessen.   

Abstract

Polyomaviruses were originally isolated in mouse and in monkey (SV40) about 50 years ago. In 1971, the first human polyomaviruses BK and JC were isolated and subsequently demonstrated to be ubiquitous in the human population. Recent studies have shown that SV40 can spread between humans and led to the identification of three new human polyomaviruses (KIPyV, MCPyV, and WUPyV). BKV, JCV, and SV40 appear harmless in healthy individuals, but possess pathogenic properties in immunosuppressed patients. Moreover they may play an etiological role in human malignancies. Epidemiologic and pathogenic studies of KIPyV, MCPyC, and WUPyV are limited so far, but MCPyV may be associated with Merkel cell carcinoma, a rare but aggressive neuroendocrine skin cancer. We describe the biology of human polyomaviruses, review their non-malignant and malignant potentials, and discuss the mechanisms by which these viruses may contribute to transformation.

Entities:  

Mesh:

Year:  2008        PMID: 19000059     DOI: 10.1111/j.1610-0387.2008.06810.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  14 in total

1.  The agnoprotein of polyomavirus JC is released by infected cells: evidence for its cellular uptake by uninfected neighboring cells.

Authors:  Onder Otlu; Francesca Isabella De Simone; Yolanda-Lopez Otalora; Kamel Khalili; Ilker Kudret Sariyer
Journal:  Virology       Date:  2014-08-23       Impact factor: 3.616

2.  A comparative study of Merkel cell, BK and JC polyomavirus infections in renal transplant recipients and healthy subjects.

Authors:  Mohamed I Husseiny; Bishoy Anastasi; Jennifer Singer; Simon F Lacey
Journal:  J Clin Virol       Date:  2010-07-27       Impact factor: 3.168

3.  Immune suppression of JC virus gene expression is mediated by SRSF1.

Authors:  Rahsan Sariyer; Francesca Isabella De-Simone; Jennifer Gordon; Ilker Kudret Sariyer
Journal:  J Neurovirol       Date:  2016-03-07       Impact factor: 2.643

4.  The clinical profile of Merkel cell carcinoma in mainland China.

Authors:  Philip I Song; Hao Liang; Wen-Qiang Wei; Yi-Qun Jiang; Jennifer S Smith; You-Lin Qiao
Journal:  Int J Dermatol       Date:  2012-09       Impact factor: 2.736

5.  SF2/ASF binding region within JC virus NCCR limits early gene transcription in glial cells.

Authors:  Elena Uleri; Patrick Regan; Antonina Dolei; Ilker Kudret Sariyer
Journal:  Virol J       Date:  2013-05-14       Impact factor: 4.099

6.  Isolation and characterization of a novel putative human polyomavirus.

Authors:  Tarik Gheit; Sankhadeep Dutta; Javier Oliver; Alexis Robitaille; Shalaka Hampras; Jean-Damien Combes; Sandrine McKay-Chopin; Florence Le Calvez-Kelm; Neil Fenske; Basil Cherpelis; Anna R Giuliano; Silvia Franceschi; James McKay; Dana E Rollison; Massimo Tommasino
Journal:  Virology       Date:  2017-03-22       Impact factor: 3.513

7.  Human polyomaviruses in skin diseases.

Authors:  Ugo Moens; Maria Ludvigsen; Marijke Van Ghelue
Journal:  Patholog Res Int       Date:  2011-09-12

8.  Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: potential clinical use.

Authors:  Valerio Berardi; Francesca Ricci; Mauro Castelli; Gaspare Galati; Gianfranco Risuleo
Journal:  J Exp Clin Cancer Res       Date:  2009-07-01

9.  Identification of a novel human polyomavirus in organs of the gastrointestinal tract.

Authors:  Sarah Korup; Janita Rietscher; Sébastien Calvignac-Spencer; Franziska Trusch; Jörg Hofmann; Ugo Moens; Igor Sauer; Sebastian Voigt; Rosa Schmuck; Bernhard Ehlers
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

10.  Bag3-induced autophagy is associated with degradation of JCV oncoprotein, T-Ag.

Authors:  Ilker Kudret Sariyer; Nana Merabova; Prem Kumer Patel; Tijana Knezevic; Alessandra Rosati; Maria C Turco; Kamel Khalili
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.